Andrew Mitchell, Leon A. Adams, Gerry MacQuillan, Jon Tibballs, Rohan vanden Driesen, Luc Delriviere – 30 January 2008 – Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease characterized by mucocutaneous and visceral telangiectasia. Hepatic involvement with vascular malformations may lead to portal hypertension, biliary ischemia, and high‐output cardiac failure. Liver transplantation is indicated for life‐threatening disease but carries significant risk from surgery and chronic immunosuppression.

Nina Singh, Cheryl Wannstedt, Lois Keyes, Debra Mayher, Lisa Tickerhoof, Mohamed Akoad, Marilyn M. Wagener, Thomas V. Cacciarelli – 30 January 2008 – The efficacy of valganciclovir as preemptive therapy for the prevention of cytomegalovirus (CMV) disease and its impact on indirect sequelae of CMV were assessed in recipient‐negative/donor‐positive (R−/D+) liver transplant recipients. Of 187 consecutive liver transplant recipients at our institution since July 2001, 36 (19.2%) belonged to the R−/D+ group.

Beyhan Demirhan, Banu Bilezikçi, A. Nihan Haberal, Şinasi Sevmiş, Zübeyde Arat, Mehmet Haberal – 30 January 2008 – During the first episode of acute cellular rejection (ACR) after liver transplantation, centrilobular changes in liver biopsy specimens may be possible indicators of subsequent episodes of ACR, early chronic rejection, or acute graft loss.

Surendra Shenoy, Karen L. Hardinger, Jeffrey Crippin, Kevin Korenblat, Mauricio Lisker‐Melman, Jeffrey A. Lowell, William Chapman – 30 January 2008 – Two‐hour postdose cyclosporine (C2) monitoring is becoming an accepted method of therapeutic drug monitoring, although it is not known whether C2 monitoring is superior to tacrolimus (FK)‐based immunosuppression. The purpose of this trial was to compare the safety, efficacy, and pharmacoeconomics of cyclosporine A (CsA) monitored by C2 levels versus FK monitored by trough levels in de novo liver transplant recipients.

Matteo Donadon, Alessandro Giacomoni, Andrea Lauterio, Abdallah Slim, Vincenzo Pirotta, Iacopo Mangoni, Luciano De Carlis – 30 January 2008

Katie Snape, Louise Izatt, Paul Ross, David Ellis, Kathy Mann, John O'Grady – 30 January 2008

Mazen Alsatie, Prashant Pandya, Naga P. Chalasani – 30 January 2008

Evangelos Cholongitas, Vibhakorn Shusang, George V. Papatheodoridis, Laura Marelli, Pinelopi Manousou, Nancy Rolando, David Patch, Keith Rolles, Brian Davidson, Andrew K. Burroughs – 30 January 2008 – Liver transplantation (LT) is the only therapeutic option for end‐stage primary sclerosing cholangitis (PSC), but PSC can recur (rPSC) in some patients after LT. The aim of our study was to evaluate the risk factors associated with rPSC. Between 1989 and 2004, 69 patients receiving transplantation for PSC (42 male, mean age 41.9 yr).

Ashokkumar Jain, Rajeev Sharma, Charlotte Ryan, Georgious Tsoulfas, Mark Orloff, Peter Abt, Randeep Kashyap, Pam Batzold, Lisa Sauberman, Saman Safadjou, Maureen Graham, Adel Bozorgzadeh – 30 January 2008 – With the current immunosuppressive regimens, graft loss secondary to immunological reasons after successful liver transplantation is a rarity; acute rejections, however, do occur, with the majority of them being steroid‐responsive.

Santiago Tome, Adnan Said, Michael R. Lucey – 30 January 2008